Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.

Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.

Abstract: The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.

Abstract: The present invention relates methods of treatment using BMP6 antagonists.

Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.

Abstract: The present invention relates methods of treatment using BMP6 antagonists.

Abstract: Disclosed herein are methods for linking non-coding variants and candidate genes that are associated with one another through long-range chromatin interactions. Thus, these non-coding variants may be involved in the expression of a candidate gene and therefore, serve as possible therapeutic targets for treating diseases in which the expression fo the candidate gene is dysreguated. A non-coding variant can be linked to a candidate gene by analyzing datasets including chromatin accessibility data (e.g., ATAC-seq data), protein-chromatin binding site pairing data, and/or chromatin contact profile. For example, a non-coding variant can be linked to a candidate gene by identifying an enhancer-promoter loop through a long range chromatin interaction. As another example, a non-coding variant can be linked to a candidate gene through a statistical eQTL analysis.

Abstract: The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.

Abstract: The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.

Abstract: The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.

Abstract: The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.

Abstract: The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.

Abstract: Prognostic methods useful in assessing patients who have received a transplant and reagents that can be used to carry out those methods are provided. The inventions are based, in part, on our analysis of gene expression in renal allografts and clinical parameters, i.e., variables associated with the donor, the recipient and/or the graft. The genes that can be assessed include those encoding agents that mediate inflammation, immune activation, and cell death (we may refer to these genes as “inflammatory”, “immune” or “cytoprotective”). Surprisingly, the levels of gene expression could predict the occurrence of DGF, AR, and the quality of later graft function even when analyzed shortly after (e.g., after vascular anastomosis and tissue reperfusion). We also found that clinical parameters available at the time of transplantation correlate with decreased graft health and can be considered in combination with gene expression to evaluate a patient's risk for an adverse outcome.

Abstract: The present invention features prognostic methods useful in assessing patients who have received a transplant and reagents, optionally packaged as kits or organized as arrays, that can be used to carry out those methods. The inventions are based, in part, on our analysis of gene expression in renal allografts and clinical parameters, such as the age of the donor. The clinical parameters include one or more variables associated with the recipient (e.g., the recipient's age and/or race); one or more variables associated with the graft (e.g., whether the graft is obtained from a living donor or a cadaver and the ischemic time); and variables associated with the donor (e.g., the donor's age and/or race). The genes that can be assessed include those encoding agents that mediate inflammation, immune activation, and cell death (we may refer to these genes below as “inflammatory”, “immune” or “cytoprotective”).

Abstract: A method for predicting the success of a new chemical entity, including the steps of providing a signal related to the new chemical entity, providing a therapeutic index, providing a conditional probability table, providing a prior probability distribution, providing a prior N, and calculating a posterior probability distribution for the new chemical entity. An apparatus for predicting the success of a new chemical entity including an input for a signal related to the new chemical entity, a therapeutic index, a conditional probability table, a prior probability distribution, a prior N, and a processor calculating a posterior probability distribution for the new chemical entity.